Results 121 to 130 of about 92,066 (229)

Febrile Neutropenia in Intensive Care Unit

Southwest Respiratory and Critical Care Chronicles, 2015
Febrile neutropenia is a serious complication of cancer treatment and causes significant morbidity and mortality, especially when these patients present with sepsis or septic shock requiring intensive care unit admission.
Nattamol Hosiriluck, Saba Radhi
doaj  

Neutropenia febril

, 2015
O desenvolvimento de febre no doente com neutropenia induzida por quimioterapia mantém-se uma situação clinica muito desafiante na área oncológica. Apesar da evolução contínua na prevenção de infeção, a neutropenia febril mantém-se como uma complicação frequente em doentes oncológicos sob quimioterapia. Esta síndrome é considerada uma emergência médica
Atalaia, G, Vasconcelos, P, Bragança, N
openaire   +1 more source

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

British Journal of Haematology, Volume 209, Issue 3, Page 1146-1157, September 2026.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You   +7 more
wiley   +1 more source

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups [PDF]

, 2011
Matthias Schwenkglenks, Pettengell, R, Schwenkglenks, Matthias, Pettengell, Ruth, Ruth Pettengell, Schwenkglenks, M   +5 more
core   +1 more source

Brucella Melitensis: A Rare Cause of Febrile Neutropenia

, 2010
Although brucellosis is endemic in Middle Eastern and Mediterranean countries, febrile neutropenia caused by Brucella species has rarely been reported in childhood.
Arman, Dilek, Dilek Arman, Citak, Elvan Caglar, Elvan Caglar Citak   +3 more
core   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, Volume 209, Issue 3, Page 1230-1238, September 2026.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

The first febrile neutropenia in DOC group.

, 2019
The bars represent the numbers of patients experienced the first occurrence time of febrile neutropenia in DOC group.
Yoshihiko Furuya (6612659)
core   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

British Journal of Haematology, Volume 209, Issue 3, Page 1386-1390, September 2026.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan, Hannah Al‐Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J. Wilson, Ke Xu, Kate Stringaris, Samah Alimam, Kavita Raj, Rajeev Gupta, Panagiotis Kottaridis, Anish Tailor, Rebecca Burgoyne, Marc R. Mansour, Asim Khwaja, Rob Sellar, Elspeth M. Payne, Jenny O'Nions   +19 more
wiley   +1 more source

Causes of neutropenia in the present series of febrile neutropenia episodes.

, 2019
Causes of neutropenia in the present series of febrile neutropenia episodes.
Lucas F. De Candia (7610519), Oscar Bottasso (328465), Gervasio F. Sasia (7610516), Matias A. Gruvman (7610522), María S. Rodríguez (3030198), Mauro Tortolo (7610510), Alcides A. Greca (7610525), Roberto L. Parodi (7610504), Mariana Lagrutta (7610507), Estefanía Navall (7610513)   +9 more
core   +1 more source

Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non‐Small Cell Lung Cancer

Cancer Science, Volume 117, Issue 9, Page 2535-2542, September 2026.
The flow of this trial and the treatment schedule of adjuvant chemotherapy with nedaplatin plus docetaxel for completely resected non‐small cell lung cancer (NSCLC) (A). The primary endpoint of this study was tolerability, assessed by the completion rate of the planned four chemotherapy cycles. As a result, it was 74.3%, exceeding that reported for the
Koji Teramoto, Ryosuke Kaku, Tomoyuki Igarashi, Masayuki Hashimoto, Shoji Kitamura, Makoto Motoishi, Yuji Suzumura, Satoru Sawai, Yataro Daigo, Jun Hanaoka   +9 more
wiley   +1 more source